Dec 31 2021 |
et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00377-5 | Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial |
| 64% higher mortality (p=0.27). RCT 342 hospitalized COVID-19 patients with hypoxia and signs of cytokine release syndrome in Belgium, showing no significant difference in time to clinical improvement, mortality, or other outcomes with IL-1 blockade (anakinra) or IL-6 b.. | ||
May 24 2021 |
et al., Leukemia, doi:10.1038/s41375-021-01299-x | Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 |
| Prospective observational study of 30 hospitalized COVID-19 patients requiring ventilatory support in Italy, showing improved ventilatory status and survival with siltuximab treatment, particularly with the reduction of IL-8 and PTX3 leve.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.